| Though grant applications are strictly confidential, NIAID is pleased to have permission to publish this outstanding phase II small business innovation research application, submitted electronically on November 30, 2005.
We wish to thank the chief executive officer of RiboNovix,
Alison Taunton-Rigby, Ph.D., and principal investigator, Cheryl Murphy,
Ph.D., for allowing us to post their application, Identification of E.
coli anti-infective rRNA targets, as a model for other applicants.
Though a small amount of confidential information and intellectual property has been removed, this application is a unique and valuable resource for our readers. Other than these minor changes, it is exactly the same application that NIAID funded. We've also included the summary statement with minor deletions to protect confidentiality.
Please note that the application is copyrighted. It may
be used for nonprofit educational purposes provided the documents remain intact and unchanged and both RiboNovix and NIAID are credited.
Download
and view
 Be sure you have Adobe
Acrobat Reader or another PDF reader installed. Keep in mind that these are large files
and may take some time to download.- Download and view the
phase II application.
- Download and view the summary statement.
For more guidance, see our Advice
on NIH SBIR and STTR Grant Applications. If you have questions or comments, please contact the Office of Innovation and Special Programs. |
